Kiora Pharmaceuticals

Kiora’s phase 1 ABACUS study of KIO-301 in retinitis pigmentosa published in Nature Medicine; phase 2 trial underway

Kiora Pharmaceuticals' Phase 1 ABACUS-1 study of KIO-301 demonstrates short-term ocular safety and feasibility in patients with late-stage retinitis pigmentosa. The Phase 2 trial is underway to evaluate functional visual improvements and compare them to a control group.

SourceKiora Pharmaceuticals·JournalNature Medicine·TypeExperimental study·DateApr 14, 2026

Kiora's investigational treatment for retinitis pigmentosa, KIO-301, demonstrates visual function restoration in patients who are blind

KIORA's treatment demonstrates restoration of visual function in patients with retinitis pigmentosa. KIO-301 shows promise as a potential cure for blindness due to the degenerative eye disease.

SourceKiora Pharmaceuticals·DateApr 27, 2023